Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores

• Status: Withdrawn
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a multiple center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection administered intrathecally before surgery in patients with high Pain Catastrophizing Scale (PCS) scores undergoing mastectomy with immediate tissue expander or implant placement.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adynxx, Inc.
• Collaborator: National Institute on Drug Abuse (NIDA)

Criteria

Inclusion Criteria:

• Score of 16 or greater on the PCS scale

• Scheduled to undergo unilateral or bilateral mastectomy with immediate tissue expander or implant placement

• American Society of Anesthesiologists Physical Status Classification System ≤ 3

• Medically stable for this surgery with general anesthesia and intrathecal administration of study drug as determined by the Investigator

• Body mass index of 18-45 kg/m2

• Have a stable medical regimen (for prescribed medications) for ≥ 7 days before randomization

• Able to read and understand study instructions in English or Spanish, and willing and able to comply with all study procedures

Exclusion Criteria:

• Prior breast surgery in the index breast (either breast for bilateral surgery) in the last two years, other than biopsies and small/moderate volume lumpectomies

• Induction chemotherapy or plans for adjunctive chemotherapy or any radiotherapy within 21 days of surgery

• Known spinal deformities or cutaneous infection in the lumbar area that would preclude intrathecal administration of study drug

• Planned use of liposomal formulated or long-acting local anesthetics, extended release opioid formulations (e.g., Oxycontin), long half-life opioids (e.g., methadone), or drugs with potential for adverse cognitive or memory effects (e.g., ketamine, scopolamine, or propranolol) preoperatively and/or at any time through the duration of the study

• Use of more than 40 mg per day (on average) of oral morphine or its equivalent within 1 month prior to randomization

• Current neurologic disorder, which could confound the assessment of pain

• Unstable mental condition which would prevent the patient from understanding the nature and scope of the study and/or evidence of an uncooperative attitude in the opinion of the Investigator

• Women who are pregnant or nursing

• Participation in a clinical trial with the last dose or intervention within 1 month of randomization, or planned treatment in a clinical trial during this study

• Previous participation in any study involving brivoligide injection